PHARMACY POLICY STATEMENT
Indiana Medicaid

DRUG NAME	Doptelet (avatrombopag)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Doptelet, approved by the FDA in 2018, is a small molecule thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adults with chronic liver disease (CLD) who are scheduled to undergo a procedure, and for adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TPO is important for regulating thrombopoiesis. The agonistic effect of Doptelet upregulates the production of platelets. TPO receptor agonists (TPO-RA) have been associated with thrombotic and thromboembolic complications. Doptelet should not be administered in an attempt to normalize platelet counts. Doptelet was the first TPO receptor agonist approved for the indicated CLD population.

Thrombocytopenia is a condition of low platelet counts. It is the most common hematologic complication in patients with CLD, and 1% experience severe thrombocytopenia (platelet count <50,000/µL). Advanced disease often requires numerous medical and/or surgical diagnostic and therapeutic procedures. Thrombocytopenia may be associated with increased bleeding risk in these invasive procedures.

Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by low levels of platelets. ITP duration of less than 3 months is referred to as newly diagnosed, 3-12 months as persistent, and greater than 12 months is considered chronic.

Doptelet (avatrombopag)

For **reauthorization**:
1. Doptelet will not be reauthorized for continuous use.

Chronic Immune Thrombocytopenia (ITP)

For **initial**

	CLD: Added hepatology and GI as accepted specialists. Specified platelet lab must be